Arcus Capital Partners LLC Buys New Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Arcus Capital Partners LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 965 shares of the company's stock, valued at approximately $321,000.

Other large investors also recently added to or reduced their stakes in the company. Centaurus Financial Inc. raised its holdings in shares of Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock valued at $505,000 after purchasing an additional 29 shares in the last quarter. Lindenwold Advisors INC raised its holdings in Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company's stock valued at $676,000 after buying an additional 32 shares in the last quarter. Stephens Inc. AR lifted its position in shares of Medpace by 4.9% in the fourth quarter. Stephens Inc. AR now owns 752 shares of the company's stock worth $250,000 after buying an additional 35 shares during the last quarter. M&T Bank Corp boosted its stake in shares of Medpace by 1.2% during the 3rd quarter. M&T Bank Corp now owns 3,199 shares of the company's stock worth $1,068,000 after acquiring an additional 37 shares in the last quarter. Finally, Custom Index Systems LLC boosted its stake in shares of Medpace by 3.0% during the 4th quarter. Custom Index Systems LLC now owns 1,290 shares of the company's stock worth $429,000 after acquiring an additional 37 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Stock Up 0.2 %

Medpace stock traded up $0.60 during mid-day trading on Tuesday, reaching $340.77. The company had a trading volume of 372,411 shares, compared to its average volume of 274,333. The company has a 50 day moving average of $343.26 and a 200-day moving average of $347.75. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The firm has a market cap of $10.59 billion, a price-to-earnings ratio of 29.84, a PEG ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. On average, analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. William Blair restated an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Robert W. Baird boosted their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. TD Cowen lowered their target price on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research note on Wednesday, October 23rd. Finally, Baird R W downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Medpace presently has a consensus rating of "Hold" and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.